Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

Abbott Laboratories agreed to pay $385 million to settle a DOJ lawsuit over contaminated baby formula. The DOJ alleged Abbott knowingly allowed the sale of contaminated formula and ignored safety issues at its Sturgis and Arizona factories. The settlement resolves claims from 2018 to 2022, with Abbott not admitting fault.

Abbott Laboratories will pay $384 million to resolve claims it sold potentially contaminated baby formula through Medicaid and WIC programs. New York will receive $9.3 million, with $5.3 million going directly to the state. The settlement follows a 2025 lawsuit alleging safety standard violations and misled inspections.